Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
Blood Adv
.
2025 Feb 25;9(4):950-953.
doi: 10.1182/bloodadvances.2024014889.
Authors
Samer Al Hadidi
1
,
Obada Ababneh
2
,
Carolina Schinke
1
,
Sharmilan Thanendrarajan
1
,
Clyde Bailey
1
,
Robert Smith
1
,
Susan Panozzo
1
,
Daisy Alapat
3
,
Guido Tricot
1
,
John Shaughnessy Jr
1
,
Fenghuang Zhan
1
,
Jeffrey Sawyer
1
,
Eric R Siegel
4
,
Bart Barlogie
1
,
Frits van Rhee
1
,
Maurizio Zangari
1
Affiliations
1
Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR.
2
Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
3
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR.
4
Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR.
PMID:
39786380
PMCID:
PMC11934280
DOI:
10.1182/bloodadvances.2024014889
No abstract available
Grants and funding
P01 CA055819/CA/NCI NIH HHS/United States